Percorso:ANSA > Nuova Europa > Slovenia > Slovenia: 400 mn for high-tech centre for biosimilars

Slovenia: 400 mn for high-tech centre for biosimilars

One of the largest investments in the country

09 March, 17:06
(ANSA) - BELGRADE, MAR 9 - LEK d.d., a member of the Sandoz Group, plans to invest an estimated 400 million euros in Lendava, Slovenia, making it one of the largest foreign direct investments in Slovenia's history and the largest single investment in Lek's history, according to a statement released by the Slovenian government today. The investment will be used to establish a high-tech manufacturing facility for biosimilar drugs. The Slovenian government added that Lek is expected to begin construction this year, with full operation of the production centre with low environmental impacts scheduled for the end of 2026.

"Slovenia today is a politically stable, orderly and attractive country in all respects. Our economic environment is resilient and predictable, we have a skilled and highly educated workforce, an excellent geo-strategic location and a well-developed infrastructure," Slovenia prime minister Robert Golob commented. (ANSA).

© Copyright ANSA - All rights reserved